Representative Elijah Cummings, D-Maryland, and Senator Bernie Sanders, I-Vermont, have sent letters to executives of 3 generic drug makers in which they ask for drug pricing information as part of a probe into the rising cost of generics.
Representative Elijah Cummings, D-Maryland, and Senator Bernie Sanders, I-Vermont, have sent letters to executives of the generic drug makers Mylan, Teva, and Heritage Pharmaceuticals, asking for drug pricing information as part of a probe into the rising cost of generics.
Cummings and Sanders originally sought information on drug price increases in 2014, sending document requests to 14 generic drug makers. Among those companies, the 3 who received letters from the lawmakers this week did not produce documents, despite what Cummings and Sanders say were repeated inquiries and discussions with the companies’ legal teams.
Cummings’ and Sanders’ letters come on the heels of the May 10 filing of a complaint by 44 US states that alleges that manufacturers coordinated their efforts to inflate the prices of several drugs covered in the 2014 probe.
Connecticut’s Attorney General, William Tong, recently released the full and unredacted complaint against drug makers including Teva, Mylan, Pfizer, Sandoz, and others. According to the complaint, the generic drug industry “would systematically and routinely communicate with one another directly, divvy up customers to create an artificial equilibrium in the market, and then maintain anticompetitively high prices,” and the drug makers “embarked on one of the most egregious and damaging price-fixing conspiracies in the history of the United States.”
The complaint also alleges that Mylan, Teva, and Heritage coordinated to obstruct Cummings’ and Sanders’ 2014 investigation into price increases. In their letters, Cummings and Sanders warn the drug makers that obstructing or evading a Congressional investigation is in violation of federal law.
Cummings and Sanders are now asking the companies for documents including those detailing revenues, expenses, sales contracts, and profit projections for specific drugs, as well as documents that would identify phone calls between employees of Heritage, Mylan, and Teva. The lawmakers have given the companies until August 28 to respond to their request.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.